In addition to point mutations in the kinase domain within the BCR::ABL1 protein, other factors that may cause CML to become resistant to dasatinib include activation of the Gab2 or Akt pathway, reduction of FOXO1 or PTEN expression, and activation of Fyn or Lyn kinase.11, 12, 13, 14. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.